Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 



